Journal Article

Impact of Concomitant Antiblastic Chemotherapy and Highly Active Antiretroviral Therapy on Human Immunodeficiency Virus (HIV) Viremia and Genotyping in HIV-Infected Patients with Non-Hodgkin Lymphoma

Cecilia Simonelli, Stefania Zanussi, Roberta Cinelli, Luigino Dal Maso, Giampiero Di Gennaro, Monica D'Andrea, Guglielmo Nasti, Michele Spina, Emanuela Vaccher, Paolo De Paoli and Umberto Tirelli

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 37, issue 6, pages 820-827
Published in print September 2003 | ISSN: 1058-4838
Published online September 2003 | e-ISSN: 1537-6591 | DOI: http://dx.doi.org/10.1086/377204
Impact of Concomitant Antiblastic Chemotherapy and Highly Active Antiretroviral Therapy on Human Immunodeficiency Virus (HIV) Viremia and Genotyping in HIV-Infected Patients with Non-Hodgkin Lymphoma

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

We evaluated the replication and resistance patterns of human immunodeficiency virus (HIV) strains recovered from HIV-infected patients with non-Hodgkin lymphoma (NHL) who were receiving chemotherapy (CT) concomitant with highly active antiretroviral therapy (HAART). We analyzed virological response to HAART in 35 patients with HIV and NHL who were treated with a cyclophosphamide-doxorubicin-vincristine-prednisone chemotherapy regimen and HAART and the virological response in 26 HIV-infected patients with CD20 cell-positive NHL who were treated with rituximab and cyclophosphamide-doxorubin-etoposide therapy. Genotype and virtual phenotype analyses were performed at baseline and when virological failure occurred. Only 9 patients met the criteria for virological failure. Genotype and virtual phenotype analyses demonstrated that, during CT administration, new mutations might occur, but there were no significant changes in the preexisting resistance patterns. Our data show that combination therapy consisting of CT and HAART is feasible and that the virological response can be maintained in the majority of patients receiving this treatment.

Journal Article.  3738 words.  Illustrated.

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.